The UCSF HIV Clinical Trials Unit (CTU) will study treatment of HIV and its complications and prevention of HIV transmission in resource rich and poor settings through the ACTG and IMPAACT networks. This newly formed CTU creates a dynamic research agenda spanning pediatric to adult disease and features accomplished and innovative researchers, a cross-cutting research agenda, HIV infected clinic populations totaling 14,000, experienced clinical trials staff, strong mentoring programs and community participation. Dr. Havlir, chief of the HIV/AIDS Division at San Francisco General Hospital will direct the CTU and lead the adult UCSF Clinical Research Site (CRS) affiliated with ACTG;Dr. Wara will lead the pediatric, adolescent and pregnant women CRS, working through IMPAACT;Dr. Kamya will lead the adult CRS of Makerere University/Infectious Diseases Institute in Uganda, as a site for the ACTG. Our CTU contributions will occur in the NIH high priority research areas of optimization of clinical management and co-morbidities;translational research/drug development;prevention of mother to child transmission and vaccines. We will closely collaborate with the VTN/HPTN-affiliated San Francisco Department of Public Health prevention CTU in promoting a coordinated approach to prevention and treatment research in our community. Our goals:
Aim 1 : Design and conduct research to define simple, safe and lifelong antiretroviral treatment (ART) strategies for children and adults;new drugs and novel agents including vaccines for HIV and its complications;innovative approaches to treat HIV co-morbidities such as TB, malaria, HPV, hepatitis B and C, and studies of viral dynamics, reservoirs, and genomics to understand pharmacokinetics and treatment responses in HIV infected participants enrolled from CRS sites at UCSF and Makerere University.
Aim 2. Integrate the HIV treatment and prevention research agenda at the scientific, operational and community level by catalyzing scientific exchange, operations, and community outreach between prevention and treatment groups, testing novel strategies to prevent vertical and horizontal transmission.
Aim 3. Foster the development of the next generation of patient based researchers by mentoring junior investigators, leveraging support of existing funding training programs such as Fogarty and CFAR.
Aim 4. Conduct research with community-based input and outreach through vibrant community advisory boards and CTU support of community education and dissemination of research findings. The relevance of this research is that the studies will define new standards for the treatment of HIV disease and its complications and will improve ways to prevent transmission of HIV from mother to child. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-MH-A (M1))
Program Officer
Welsch, Sue A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Jakubowski, Aleksandra; Snyman, Katherine; Kwarisiima, Dalsone et al. (2018) High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial. PLoS One 13:e0198912
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Petersen, Maya; Balzer, Laura; Kwarsiima, Dalsone et al. (2017) Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA 317:2196-2206
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Balzer, Laura B; van der Laan, Mark J; Petersen, Maya L et al. (2016) Adaptive pre-specification in randomized trials with and without pair-matching. Stat Med 35:4528-4545
Chamie, Gabriel; Clark, Tamara D; Kabami, Jane et al. (2016) A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV 3:e111-9
Ssemmondo, Emmanuel; Mwangwa, Florence; Kironde, Joel L et al. (2016) Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda. J Acquir Immune Defic Syndr 73:e46-e50
Balzer, Laura B; Petersen, Maya L; van der Laan, Mark J et al. (2016) Targeted estimation and inference for the sample average treatment effect in trials with and without pair-matching. Stat Med 35:3717-32

Showing the most recent 10 out of 54 publications